Search This Blog

Wednesday, August 30, 2023

Alzamend Applies for Phase IIA Clinical Trial of AL001, a Next-Gen Lithium

 

  • Safety aspects of AL001 development may qualify for (505)(b)(2) pathway for FDA approval
  • Alzamend’s recently completed a Phase IIA Study of AL001 in Alzheimer’s and healthy patients that identified a candidate dose that is unlikely to require therapeutic drug monitoring

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.